TFX benefits from a diversified product portfolio in the first quarter of 2025, with strength in the Surgical and Interventional segments.
Teleflex Incorporated (NYSE:TFX ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Lawrence Keusch - VP-IR & Strategy Development Liam Kelly - Chairman, President & Chief Executive Officer John Deren - Executive VP & Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Michael Sarcone - Jefferies Jayson Bedford - Raymond James Vikramjeet Singh Chopra - Wells Fargo Matthew O'Brien - Piper Sandler Anthony Petrone - Mizuho Group Shagun Singh - RBC Richard Newitter - Truist Securities Craig Bijou - Bank of America Michael Polark - Wolfe Research Mike Matson - Needham Operator Good morning, ladies and gentlemen, and welcome to the Teleflex First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded, and we will be available on the company's website for replay shortly.
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $3.21 per share a year ago.
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex's (TFX 2.89%) fourth-quarter 2024 earnings conference call, held on February 27, 2025, revealed significant strategic shifts for the medical device company. In a transformative announcement, Teleflex outlined plans to acquire the Vascular Intervention business from Biotronik and separate into two publicly traded companies.
Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player.
TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.
Teleflex Incorporated (NYSE:TFX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Lawrence Keusch - VP-IR & Strategy Development Liam Kelly - Chairman, President & CEO Thomas Powell - EVP & CFO John Deren - Corporate VP and Chief Accounting Officer Conference Call Participants Patrick Wood - Morgan Stanley Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Larry Biegelsen - Wells Fargo Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Craig Bijou - Bank of America Michael Polark - Wolfe Research Mike Matson - Needham Operator Good morning, ladies and gentlemen, and welcome to the Teleflex Fourth Quarter 2024 Earnings Conference Call. At this time all participants have been placed in a listen-only mode.
On Thursday, Teleflex Incorporated TFX will pursue a plan to separate into two new, independent, publicly traded companies:
Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teleflex (TFX) came out with quarterly earnings of $3.89 per share, beating the Zacks Consensus Estimate of $3.86 per share. This compares to earnings of $3.38 per share a year ago.